New data from a real-life study show that afatinib followed by osimertinib provided a median overall survival of up to almost four years (45.7 months) in patients with mutated EGFR lung cancer (Del19 and T790M positive). This has been announced from Boehringer Ingelheim, explaining that these data have been obtained from an updated analysis of the GioTag observational study and have been published in the scientific journal Future Oncology.
Until now, only 2-year and 2.5-year overall survival rates were available from the GioTag study. This new analysis evaluates the updated data of a subgroup of patients with electronic health records available in the US. UU. Specifically, these new data assume that after a median follow-up time of 30.3 months, the median overall survival was almost three and a half years (41.3 months) in patients with non-small cell lung carcinoma (NSCLC). of the T790M mutation acquired and treated in a real clinical setting; and the updated SG rate at two years was 80 percent.
In the words of Maximilian J. Hochmair, pulmonologist at the department of internal medicine and pulmonology at Krankenhaus Nord, Klinik Floridsdorf, and research coordinator of the study, “as many patients with this type of lung cancer end up acquiring resistance to the ITCs of EGFR, it is It is important to consider the order of administration of these therapies to offer patients the maximum treatment options in the future. The updated findings of the GioTag study provide data showing that afatinib followed by osimertinib is a viable sequential therapeutic option for patients with NSCLC with the mutated epidermal growth factor receptor (EGFR M +). ”
Positive tumors for the mutation
Another highlight of this study is that overall survival is particularly promising in patients with tumors positive for the Del19 mutation at the start of afatinib treatment.
As observed in the study, in these patients, the median overall survival was 45.7 months and the two-year overall survival rate was 82 percent. The median time in treatment with sequential afatinib and osimertinib was 28.1 months overall, and 30.6 months in patients with tumors positive for Del19.
Thus, Victoria Zazulina, corporate vice president and global head of oncology and medicine at Boehringer Ingelheim, concluded that: “The continuous clinical development of the new tyrosine kinase inhibitors (ITCs) of EGFR offers additional treatment options to patients with CPNM EGFR M + and raises questions about the optimal sequence. Since there are no targeted treatment options established so far after the failure of osimertinib, there are reasons to assess the administration of osimertinib in the second line, after the second generation EGFR ITCs. The real-life data from the GioTag study support the reasoning of the sequential use of afatinib and osimertinib in patients with MFR CPNM M + with the Del19 mutation ”.